Natural history of recurrence of hepatitis C (HEP CR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS).

被引：0
|
作者：
Fasola, CG [1 ]
Netto, GJ [1 ]
Christensen, LL [1 ]
Molmenti, EP [1 ]
Gonwa, TA [1 ]
Goldstein, RM [1 ]
Levy, MF [1 ]
Klintmalm, GB [1 ]
机构：
[1] Baylor Univ, Med Ctr, Dallas, TX USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1870
引用
收藏
页码：639A / 639A
页数：1
相关论文
共 50 条
  • [1] Hepatitis C recurrence (HCVR) in liver transplant recipients (OLT) under mycophenolate mofetil (MMF) immunosuppression (IS): A long-term follow up
    Fasola, CG
    Netto, GJ
    Sanchez, EQ
    Chinnakotla, S
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 : 356 - 356
  • [2] Optimal dosing of mycophenolate mofetil (MMF) is necessary to delay hepatitis C recurrence (HEP CR) in liver transplant recipients.
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Sanchez, EQ
    Molmenti, EM
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Klintmalm, GB
    HEPATOLOGY, 2001, 34 (04) : 639A - 639A
  • [3] Initial clinical evidence that mofetil mycophenolate (MMF) antiviral effects may delay the recurrence of hepatitis C (HEP C) and reduce the incidence of CMB infection in HEP C liver transplant recipients (OLT).
    Fasola, CG
    Netto, G
    Jennings, LW
    Jung, GJ
    Marubashi, S
    Sanchez, EQ
    Molmenti, EP
    Gonwa, TA
    Goldstein, RM
    Klintmalm, GB
    HEPATOLOGY, 2000, 32 (04) : 290A - 290A
  • [4] Recurrence of hepatitis C in liver transplant recipients treated with mycophenolate mofetil
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1563 - 1564
  • [5] Does mofetil mycophenolate (MMF) delay hepatitis C recurrence in liver transplant patients?
    Fasola, CG
    Netto, GJ
    Jennings, LW
    Gonwa, TA
    Goldstein, RM
    Levy, MF
    Molmenti, EP
    Klintmalm, GB
    TRANSPLANTATION, 2000, 69 (08) : S120 - S120
  • [6] Mycophenolate mofetil (MMF) in pediatric liver transplant recipients
    Dhawan, A
    Lewis, PN
    Heaton, ND
    Baker, AJ
    Rela, M
    Hadzic, N
    Srinivasan, P
    MieliVergani, G
    HEPATOLOGY, 1997, 26 (04) : 1487 - 1487
  • [7] Delay of hepatitis C recurrence in liver transplant recipients: Impact of mycophenolate mofetil on transplant recipients with severe acute rejection or with renal dysfunction
    Fasola, CG
    Netto, GJ
    Christensen, LL
    Molmenti, EP
    Sanchez, EQ
    Levy, MF
    Goldstein, RM
    Klintmalm, GB
    TRANSPLANTATION PROCEEDINGS, 2002, 34 (05) : 1561 - 1562
  • [8] Conversion to mycophenolate mofetil for modulating recurrent hepatitis C in liver transplant recipients
    Kornberg, A.
    Kuepper, B.
    Wilberg, J.
    Tannapfel, A.
    Thrum, K.
    Baerthel, E.
    Hommann, M.
    Settmacher, U.
    TRANSPLANT INFECTIOUS DISEASE, 2007, 9 (04) : 295 - 301
  • [9] Mycophenolate mofetil (MMF) monotherapy improves renal dysfunction in orthotopic liver transplant (OLT) recipients without increased risk of rejection
    Raimondo, ML
    Dagher, L
    Papatheodoridis, G
    Gunsar, F
    Turchi, V
    Rolles, K
    Davidson, B
    Patch, D
    Burroughs, A
    JOURNAL OF HEPATOLOGY, 2002, 36 : 193 - 193
  • [10] Pharmacokinetics of Mycophenolate Mofetil in Pediatric Liver Transplant Recipients to Optimize MMF Dose
    Barau, C.
    Habes, D.
    Debray, D.
    Taburet, A. M.
    Furlan, V.
    THERAPEUTIC DRUG MONITORING, 2009, 31 (05) : 651 - 652
12345